CVS Health Corporation (NYSE:CVS) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer made some positive comments on the stock. He said: “Next, Wednesday got me trembling in anticipation. Why? Well, this morning has a sure winner in CVS, at least from my point of view. Now, I’m betting it’s much better now that Rite Aid’s done and Walgreens is pulling back sharply.” CVS Health Corporation (CVS): A Must-Buy Dividend Stock Leading U.S. Pharmacy and Healthcare CVS Health Corporation ( ...

Key Takeaways UnitedHealths diversification drives stability, but margins face strain from rising medical costs.Humana's benefit ratio improvement and CenterWell growth highlight stronger cost control.Humana trades at a discount to UnitedHealth, with higher earnings growth and rebound potential.In the ever-evolving health insurance landscape, UnitedHealth Group Incorporated (UNH) and Humana Inc. (HUM) stand as two dominant forces. Both companies have built resilient business models rooted in Medicare Advant ...

公司业务结构 - 公司运营两大核心业务：UnitedHealthcare（健康保险）和Optum（医疗健康服务与技术）[2] - 2024年收入结构：UnitedHealthcare占比54%，Optum占比46%，后者份额从2021年的41%持续提升[2] - Optum由三大子业务构成：Optum Health（医疗服务）、Optum Insight（数据与技术）、Optum Rx（药品福利管理）[9] UnitedHealthcare业务细分 - Medicare & Retirement部门2024年收入1395亿美元（占25%），EBITDA 84亿美元（占23%），正面临刑事调查[4] - Employer & Individual部门2024年收入745亿美元（占13%），EBITDA 45亿美元（占12%）[5] - Community & State部门2024年收入806亿美元（占15%），EBITDA 49亿美元（占13%）[7] - International部门2024年收入37亿美元（<1%），EBITDA 222亿美元，已退出巴西市场[8] Optum业务表现 - Optum Health近三年收入年均增长25%（公司整体14%），2024年收入1054亿美元（占19%），EBITDA占比达24%[10] - Optum Insight 2024年收入188亿美元（占3%），EBITDA 36亿美元（占9%）[11] - Optum Rx 2024年收入1332亿美元（占24%），EBITDA 68亿美元（占18%），面临PBM政策调整风险[12] 战略发展态势 - Optum业务收入占比持续提升，成为公司增长主要驱动力[2][14] - Medicare刑事调查与PBM政策变化构成双重挑战[15] - 公司处于关键转型期，需应对监管与市场结构变化[13]